Media Resources

2015
23 June

Health Action International Launches New Brussels Office
16 June

Health Action International Criticises JURI Support for EU Trade Secrets Directive Report
14 April

How TTIP Could Damage Access to Affordable Medicines in the European Union
15 March

Assessing the Nature, Extent and Impact of Regulation of Medicines Promotion
3 March

2014 Annual Report and Financial Statements
1 March

2014 Annual Report and Financial Statements
18 February

EU Clinical Trials Regulation: EMA Steers Away from Transparency by Misinterpreting Exception Provisions
2014
22 October

Retention of Medicines Policy in DG Health a Victory for Public Health Advocates
16 October

EMA’s Final Policy on Access to Clinical Data: Proactive Access to Some Data, But Strings Attached
14 October

EU Pharmacovigilance Public Hearings Should Be As Transparent and Independent as in US
29 September

Trading Away Access to Medicines – Revisited
29 September

Europe Seeks to Expand Big Pharma Monopoly at Expense of Poor People, Warn NGOs Ahead of TTIP Talks (2014)
12 September

Public Health in Danger with Move of Pharmaceutical Policy to DG Enterprise and Industry
1 September

Mapping External Reference Pricing Practices for Medicines
14 July

Investor-State Dispute Settlement in EU-US Trade Deal Risks Access to Affordable Medicines
24 June

EMA’s New Policy on Access to Clinical Data – About to Privatise Pharmaceutical Knowledge?
3 April

Health Action International Welcomes Adoption of New Clinical Trials Regulation by European Parliament
3 April

Health Action International Applauds Medicines Patent Pool, ViiV Healthcare Licensing Agreement for New HIV Treatment
24 March

The EU-US Trade Agreement – Proposals by Pharmaceutical Industry Undermine European Public Policymaking and Public Health
17 March

EU Regulation on Clinical Trials – Close to the Finish Line
3 March

2013 Annual Report and Financial Statements
1 March

2013 Annual Report and Financial Statements
1 February

Working Paper 4 – Competition Policy
1 February

Policy Brief 3 – Regulation of Mark-ups in the Pharmaceutical Supply Chain
1 February

Policy Brief 5 – Sales Taxes on Medicines
1 February

Policy Brief 2 – The Role of Health Insurance in the Cost-effective Use of Medicines
1 February

Working Paper 1 – External Reference Pricing
1 February

Policy Brief 4 – Competition Policy
1 February

Policy Brief 1 – External Reference Pricing
1 February

Working Paper 2 – The Role of Health Insurance in the Cost-Effective Use of Medicines